bpc 157 fda warning letter peptide Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting July 23 BPC-157 Legal Status: FDA Regulations

Important Update on FDA Changes Concerning Peptides Important Update on FDA Changes Concerning Peptides **PRESS RELEASE** **Important Update on FDA Changes Concerning Peptides** We are writing to you with an important update concerning recent changes by the FDA

BPC-157 For Knee Pain: Early Reported Outcomes A report on intra-articular BPC-157 for knee pain described high rates of improvement: ~92% with BPC-157 alone, ~75% when combined with thymosin beta-4, and overall pain relief reported in 87.5% of patients

PloS One (2011) 6(7):e21800

Stop waiting for your body to catch up

Board-certified providers guide and personalize each treatment

Unfortunately, this effect vanished after time ranging from 6 h to 4 days